paraproteinemias

Summary

Summary: A group of related diseases characterized by an unbalanced or disproportionate proliferation of immunoglobulin-producing cells, usually from a single clone. These cells frequently secrete a structurally homogeneous immunoglobulin (M-component) and/or an abnormal immunoglobulin.

Top Publications

  1. ncbi Paraproteinemic neuropathy
    Justin Y Kwan
    Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, TX 77030, USA
    Neurol Clin 25:47-69. 2007
  2. ncbi Hemostatic dysfunction in paraproteinemias and amyloidosis
    Maurizio Zangari
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Semin Thromb Hemost 33:339-49. 2007
  3. ncbi Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
    Fenghuang Zhan
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
    Blood 99:1745-57. 2002
  4. ncbi New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells
    Ernesto Pérez-Persona
    Department of Hematology, University Hospital, Salamanca, Spain
    Blood 110:2586-92. 2007
  5. ncbi Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma
    Therese Standal
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Haematologica 89:174-82. 2004
  6. pmc Differences in immunoglobulin light chain species found in urinary exosomes in light chain amyloidosis (Al)
    Marina Ramirez-Alvarado
    Department of Biochemistry and Molecular Biology, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    PLoS ONE 7:e38061. 2012
  7. ncbi Renal lesions associated with plasma cell dyscrasias: practical approach to diagnosis, new concepts, and challenges
    Guillermo A Herrera
    Pathology Department, Nephrocor Laboratory, 1700 N Desert Drive, Tempe, AZ 85281, USA
    Arch Pathol Lab Med 133:249-67. 2009
  8. ncbi Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
    Meletios Dimopoulos
    University of Athens, Athens, Greece
    Blood 117:4701-5. 2011
  9. ncbi Prevalence of monoclonal gammopathy of undetermined significance
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, Minn 55905, USA
    N Engl J Med 354:1362-9. 2006
  10. pmc Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease
    Derralynn Hughes
    Department of Academic Haematology, Royal Free Hospital and University College Medical School, London, UK
    Br J Haematol 138:676-86. 2007

Detail Information

Publications201 found, 100 shown here

  1. ncbi Paraproteinemic neuropathy
    Justin Y Kwan
    Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, TX 77030, USA
    Neurol Clin 25:47-69. 2007
    ..A methodical diagnostic approach to patients who have a plasma cell dyscrasia and neuropathy is necessary to ensure the appropriate detection of more widespread systemic involvement...
  2. ncbi Hemostatic dysfunction in paraproteinemias and amyloidosis
    Maurizio Zangari
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Semin Thromb Hemost 33:339-49. 2007
    ....
  3. ncbi Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
    Fenghuang Zhan
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
    Blood 99:1745-57. 2002
    ..Thus, novel candidate MM disease genes have been identified using gene expression profiling and this profiling has led to the development of a gene-based classification system for MM...
  4. ncbi New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells
    Ernesto Pérez-Persona
    Department of Hematology, University Hospital, Salamanca, Spain
    Blood 110:2586-92. 2007
    ..001). Our results show that multiparameter FC evaluation of BMPC at diagnosis is a valuable tool that could help to individualize the follow-up strategy for MGUS and SMM patients...
  5. ncbi Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma
    Therese Standal
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Haematologica 89:174-82. 2004
    ..It is involved in a number of physiologic and pathologic events including adhesion, angiogenesis, apoptosis, inflammation, wound healing and tumor metastasis. We wanted to investigate the potential role of OPN in multiple myeloma...
  6. pmc Differences in immunoglobulin light chain species found in urinary exosomes in light chain amyloidosis (Al)
    Marina Ramirez-Alvarado
    Department of Biochemistry and Molecular Biology, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    PLoS ONE 7:e38061. 2012
    ..Our results showed that urinary exosomes may have tremendous potential in furthering our understanding of the pathophysiology and diagnosis of plasma cell dyscrasia related kidney diseases...
  7. ncbi Renal lesions associated with plasma cell dyscrasias: practical approach to diagnosis, new concepts, and challenges
    Guillermo A Herrera
    Pathology Department, Nephrocor Laboratory, 1700 N Desert Drive, Tempe, AZ 85281, USA
    Arch Pathol Lab Med 133:249-67. 2009
    ..Research in the laboratory has helped considerably in providing a solid conceptual understanding of how renal damage occurs...
  8. ncbi Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
    Meletios Dimopoulos
    University of Athens, Athens, Greece
    Blood 117:4701-5. 2011
    ..The skeletal survey remains the standard method for imaging screening, but magnetic resonance imaging frequently provides valuable diagnostic and prognostic information. Most of these tests are repeated during follow-up or at relapse...
  9. ncbi Prevalence of monoclonal gammopathy of undetermined significance
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, Minn 55905, USA
    N Engl J Med 354:1362-9. 2006
    ..We used sensitive laboratory techniques to ascertain the prevalence of MGUS in a large population in a well-defined geographic area...
  10. pmc Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease
    Derralynn Hughes
    Department of Academic Haematology, Royal Free Hospital and University College Medical School, London, UK
    Br J Haematol 138:676-86. 2007
    ..Future studies should focus on the utility of early treatment to prevent immunoglobulin abnormalities and multiple myeloma...
  11. ncbi Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios
    Arthur R Bradwell
    Department of Immunity and Infection, Medical School, University of Birmingham, UK
    Clin Chem 55:1646-55. 2009
    ..As an alternative, clonality might be determined by measuring the separate light chain types of each Ig class to allow numerical assessment of Ig'kappa/Ig'lambda ratios, analogous to free light chain kappa/lambda ratios...
  12. pmc Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy
    Madhav V Dhodapkar
    Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, New York, NY 10021, USA
    J Exp Med 198:1753-7. 2003
    ....
  13. ncbi Familiality of benign and malignant paraproteinemias. A population-based cancer-registry study of multiple myeloma families
    Helga M Ogmundsdottir
    Molecular and Cell Biology Laboratory, Icelandic Cancer Society, Skogarhlid 8, 105 Reykjavik, Iceland
    Haematologica 90:66-71. 2005
    ..The current study is the first population- and cancer-registry-based survey to investigate familiality of premalignant or malignant B-cell proliferation...
  14. pmc Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders
    Linda Morris Brown
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
    Blood 111:3388-94. 2008
    ..Risks for MGUS were generally of similar magnitude. Our results indicate that various types of immune-mediated conditions might act as triggers for MM/MGUS development...
  15. ncbi Renal manifestations of plasma cell disorders
    Nelson Leung
    Division of Nephrology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Am J Kidney Dis 50:155-65. 2007
  16. ncbi Pulmonary manifestations of light chain deposition disease
    Lisa Rho
    Division of Pulmonary, Critical Care and Sleep Medicine, New York, USA
    Respirology 14:767-70. 2009
    ..Rarely, light chains are deposited in the lung. We present the pathologic and radiographic findings of three patients with biopsy-proven pulmonary light chain disease and a review of the literature...
  17. ncbi Laboratory characterizations on 2007 cases of monoclonal gammopathies in East China
    Hao Wang
    Department of Laboratory Medicine, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China
    Cell Mol Immunol 5:293-8. 2008
    ..Although TGFbeta1, an important cytokine in immune regulation, was elevated in monoclonal gammopathies, the SNPs in coding region of TGFbeta1 gene did not confer susceptibility to the development of monoclonal gammopathies in this study...
  18. ncbi Analysis of the serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and different stages of multiple myeloma
    V Scudla
    Department of Internal Medicine III, University Hospital, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
    Neoplasma 58:499-506. 2011
    ..001 and MM. More benefit may be expected from analyses using multiparametric immunophenotyping of plasma cells and molecular biology methods including gene expression analysis and proteomics...
  19. ncbi Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications
    Yukihiko Saeki
    Department of Molecular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
    Br J Haematol 123:263-70. 2003
    ..Plasma OPN levels may be a useful biomarker for assessing bone destruction in MM and distinguishing MM from MGUS or smouldering MM...
  20. ncbi [Analysis of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma]
    V Scudla
    III interní klinika LF UP a FN, Olomouc
    Klin Onkol 23:171-81. 2010
    ....
  21. ncbi Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors
    Claudio Pozzi
    Department of Nephrology and Dialysis, A Manzoni Hospital, Lecco, Italy
    Am J Kidney Dis 42:1154-63. 2003
    ..Light chain deposition disease (LCDD) is characterized by the tissue deposition of monotypical immunoglobulin light chains (LCs). The aim of this study was to investigate its clinical characteristics and prognostic factors...
  22. pmc A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma
    Madhav V Dhodapkar
    Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, New York, NY 10021, USA
    J Exp Med 197:1667-76. 2003
    ....
  23. ncbi Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis
    Helen J Lachmann
    National Amyloidosis Centre, Department of Medicine, Royal Free and University College Medical School, Royal Free Campus, London, United Kingdom
    N Engl J Med 346:1786-91. 2002
    ....
  24. pmc Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG
    A A Ilyas
    Department of Neurology and Neuroscience, UMDNJ New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103, USA
    J Neuroimmunol 193:87-93. 2008
    ..This study suggests that these anti-MAG/SGPG antibodies play a role in the pathogenesis of this neuropathy...
  25. ncbi Monoclonal gammopathy of undetermined significance predisposing to Helicobacter pylori-related gastric mucosa-associated lymphoid tissue lymphoma
    Antonio Tursi
    Department of Emergency, L Bonomo Hospital, Andria, Italy
    J Clin Gastroenterol 34:147-9. 2002
    ..We report a patient with MGUS and H. pylori infection in whom we noted the progression of gastritis to acquired gastric MALT and gastric MALT to MALT lymphoma during a 3-year follow-up...
  26. ncbi The role of glycosphingolipids in neurological disorders. Mechanisms of immune action
    R K Yu
    Department of Biochemistry and Molecular Biophysics, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond 23298 0614 USA
    Ann N Y Acad Sci 845:285-306. 1998
    ..This latter observation suggests that SGGLs may also participate in cell-mediated responses in certain inflammatory neurological disorders...
  27. ncbi Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins
    Raymond L Comenzo
    Howard 802, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Blood 107:3489-91. 2006
    ..These results justify further study of screening for hereditary variants in patients with apparent AL, and highlight the need for practical techniques for identifying fibrils extracted from tissue...
  28. ncbi Monoclonal gammopathy in extranodal marginal zone lymphoma (ENMZL) correlates with advanced disease and bone marrow involvement
    Ekatherine Asatiani
    Georgetown University Hospital, Departments of Oncology and Medicine, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA
    Am J Hematol 77:144-6. 2004
    ..0007). Prevalence of monoclonal gammopathy is higher than previously recognized and indicates advanced disease. However, the prognostic significance of the presence of monoclonal gammopathy in this population is unknown...
  29. ncbi Reduced intensity allogeneic stem cell transplantation for systemic primary amyloidosis refractory to high-dose melphalan
    Yasukazu Kawai
    First Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Matsuoka, Japan
    Eur J Haematol 72:448-50. 2004
    ..RIST may be feasible and be capable of achieving complete HR along with recovery from nephrotic syndrome with acceptable toxicity...
  30. ncbi The contributions of electron microscopy to the understanding and diagnosis of plasma cell dyscrasia-related renal lesions
    G A Herrera
    Department of Pathology, Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130, USA
    Med Electron Microsc 34:1-18. 2001
    ..This review highlights the role that electron microscopy has played and continues playing in the characterization of plasma cell dyscrasias-related renal lesions...
  31. ncbi Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis
    David C Seldin
    Boston University Medical Center, Boston Medical Center, MA, USA
    Clin Lymphoma 3:241-6. 2003
    ..No complete hematologic responses were seen, but 25% of patients had a significant reduction in Bence-Jones proteinuria. Thus, while thalidomide has activity in AL amyloidosis, it also has significant toxicity in this patient population...
  32. ncbi Peripheral neuropathies associated with monoclonal gammopathies of undetermined significance
    John J Kelly
    Department of Neurology, The George Washington University Medical Center, Washington, DC, USA
    Rev Neurol Dis 5:14-22. 2008
    ..MGUS is the most common of the PCDs associated with neurologic disorders, which are easily approached clinically by classifying them as IgM or non-IgM types...
  33. ncbi A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy
    Giancarlo Comi
    Department of Neurology, Ospedale San Raffaele, Via Olgettina 60, 20132 Milan, Italy
    J Neurol 249:1370-7. 2002
    ..Two serious adverse events occurred during the trial, both during placebo treatment. In conclusion the trial showed some short-term benefit of IVIg in about half of the patients confirming previous observation...
  34. ncbi Monoclonal gammopathies of undetermined significance: a review
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Immunol Rev 194:112-39. 2003
    ..MGUS may be associated with many different disorders, including lymphoproliferative diseases, leukemia, connective tissue disorders, dermatologic diseases, and neurologic disorders...
  35. ncbi IgM paraproteinaemic neuropathies
    Eduardo Nobile-Orazio
    Giorgio Spagnol Service of Clinical Neuroimmunology, Dino Ferrari Centre, Department of Neurological Sciences, Milan University, IRCCS Ospedale Maggiore Policlinico and Humanitas Clinical Institute, Milan, Italy
    Curr Opin Neurol 17:599-605. 2004
    ..To conduct a critical review of recent studies on the pathogenesis and treatment of IgM paraproteinaemic neuropathies and analyse their implication for patient management...
  36. ncbi Variability in immunohistochemistries of IgM M-proteins binding to sulfated glucuronyl paragloboside
    M Shiina
    Department of Neurology, Division of Neuroscience, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Tokyo 113-8655, Bunkyo, Japan
    J Neuroimmunol 116:206-12. 2001
    ..Only three patients (all in group B) showed some response to the immunotherapies. Weak reactivities to P0 and and PMP-22 might indicate the possibility of improvement after the immunotherapies...
  37. pmc Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 106:812-7. 2005
    ....
  38. ncbi Transformation of a MGUS to overt multiple myeloma: the possible role of a pituitary macroadenoma secreting high levels of insulin-like growth factor 1 (IGF-1)
    Alessandra Tucci
    Sezione di Ematologia, Spedali Civili, p le Spedali Civili 1, 25125 Brescia, Italy
    Leuk Lymphoma 44:543-5. 2003
    ....
  39. ncbi Immunotactoid keratopathy: a clinicopathologic case report and a review of reports of corneal involvement in systemic paraproteinemias
    Daniel C Garibaldi
    Eye Pathology Laboratory, Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Surv Ophthalmol 50:61-80. 2005
    Corneal deposits in association with paraproteinemias have been well described in the ophthalmic literature...
  40. ncbi Genomic abnormalities in monoclonal gammopathy of undetermined significance
    Rafael Fonseca
    Division of Hematology and Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 100:1417-24. 2002
    ..Similar translocations are found in both MGUS and MM, including t(4;14)(p16.3;q32) and t(14;16)(q32;q23). Moreover, Delta 13 is common in MGUS and unlikely to play a predominant role in the evolution of MGUS to MM...
  41. ncbi Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice
    Jerry A Katzmann
    Division of Clinical Biochemistry and Immunology, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Clin Chem 51:878-81. 2005
    ..We evaluated its diagnostic performance in clinical practice...
  42. ncbi Cardiac nonamyloidotic immunoglobulin deposition disease
    Amir A Toor
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Mod Pathol 19:233-7. 2006
    ..Concurrent amyloidosis in other organs sheds a unique perspective into the role of local microenvironment in the pathogenesis of systemic Ig deposition disease and amyloidosis...
  43. ncbi [Monoclonal gammapathies in Tunisia: epidemiological, immunochemical and etiological analysis of 288 cases]
    S Mseddi-Hdiji
    Service d Hematologie, CHU Hédi Chaker de Sfax, 3029 Sfax, Tunisie
    Pathol Biol (Paris) 53:19-25. 2005
    ..8% of the cases in our set and the free light chains (kappa or lambda) for 13.6% of the cases whereas the IgM represents 8.7% only of the 288 cases of our set which involves three cases of IgD myeloma and six cases of biclonal gammapathy...
  44. ncbi Identification and properties of glycated monoclonal IgA that affect the fructosamine assay
    Kiyotaka Fujita
    Department of Immunology, The Scripps Research Institute, 10550 North Torrey Pines Rd, La Jolla, CA 92037, USA
    Clin Chem 49:805-8. 2003
  45. ncbi Monoclonal gammopathy of undetermined significance
    Robert A Kyle
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Clin Lymphoma Myeloma 6:102-14. 2005
    ..Epidemiologic and statistical methods must be used to evaluate these associations...
  46. ncbi Extraosseus plasmacytoma of the pharynx with localized light chain deposition. Case report
    Nina Zidar
    Institute of Pathology, Faculty of Medicine, University of Ljubljana, Korytkova 2, 1000, Ljubljana, Slovenia
    Pathol Oncol Res 16:249-52. 2010
    ..A less aggressive clinical course can probably be expected than in the usual form of LCDD, but a long-term follow-up is necessary to establish the clinical significance of this variant of LCDD...
  47. ncbi Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy
    J M F Niermeijer
    Department of Neurology and Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands
    Neurology 69:50-9. 2007
    ..We therefore performed a double-blind, randomized, placebo-controlled study of combined oral cyclophosphamide and prednisone in IgM MGUS polyneuropathy...
  48. ncbi Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases
    J Buxbaum
    Department of Medicine, New York University School of Medicine, New York, USA
    Hematol Oncol Clin North Am 13:1235-48. 1999
    ..More structural analyses of material extracted from deposits in tissue may resolve this issue...
  49. ncbi A long-term study of prognosis in monoclonal gammopathy of undetermined significance
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    N Engl J Med 346:564-9. 2002
    ..A monoclonal gammopathy of undetermined significance (MGUS) occurs in up to 2 percent of persons 50 years of age or older. Reliable predictors of progression have not been identified, and information on prognosis is limited...
  50. ncbi European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Socie
    R D M Hadden
    Department of Neurology, King s College Hospital, London, UK
    Eur J Neurol 13:809-18. 2006
    ..Objectives. To prepare evidence-based and consensus guidelines on the clinical management of patients with both a demyelinating neuropathy and a paraprotein (paraproteinaemic demyelinating neuropathy, PDN)...
  51. ncbi Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mayo Clin Proc 81:693-703. 2006
    ..Updated diagnostic criteria for these disorders, risk stratification models to determine prognosis, and the current management of these diverse entitles are discussed in this review...
  52. ncbi Long-term outcome of autologous stem cell transplantation in light chain deposition disease
    Elizabeth C Lorenz
    Division of Nephrology and Hypertension, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    Nephrol Dial Transplant 23:2052-7. 2008
    ..However, the impact of ASCT on renal function is unclear. This study retrospectively reviewed the effect of ASCT on renal function in patients with LCDD...
  53. ncbi [Triclonal gammopathy and malignant immunoproliferative syndrome]
    B Grosbois
    Service de médecine interne G, CHU, Hopital Sud, Reenes, France
    Rev Med Interne 18:470-3. 1997
    ..The origin of three distinct monoclonal proteins may derive from three unrelated clones or alternatively from a single clone in which an isotype switch has occurred...
  54. ncbi Assessment of serum free light chain assays for plasma cell disorder screening in a Veterans Affairs population
    Jude M Abadie
    Department of Laboratory Medicine, University of Washington Medical School, Veterans Affairs Puget Sound Health Care System, Seattle, Washington 98108, USA
    Ann Clin Lab Sci 36:157-62. 2006
    ..Using the serum FLC results in conjunction with SPEP results improves the sensitivity and specificity for managing VA patients whose clinical presentation indicates the need to evaluate PCD...
  55. ncbi Bone marrow angiogenesis in patients with active multiple myeloma
    A Vacca
    Department of Biomedical Sciences and Oncology, University of Bari Medical School, Policlinico-Piazza Giulio Cesare, 11, I-70124 Bari, Italy
    Semin Oncol 28:543-50. 2001
    ..Both angiogenesis and MMP-2 secretion can account for intramedullary and extramedullary spreading of plasma cells in patients with active MM...
  56. ncbi [Several episodes of bacterial infections in a patient with monoclonal gammapathy of undetermined significance]
    R D García Marrero
    An Med Interna 23:452. 2006
  57. ncbi Monoclonal gammopathy of undetermined significance and exposure to breast implants
    E W Karlson
    Harvard Medical School, Boston, MA 02115
    Arch Intern Med 161:864-7. 2001
    ..Animal studies and uncontrolled case series in humans have suggested a possible association between breast implant exposure and monoclonal gammopathy...
  58. ncbi Type I Gaucher disease with severe skeletal destruction, extraosseous extension, and monoclonal gammopathy
    A Kaloterakis
    Second Academic Department of Internal Medicine, University of Athens, Hippocration Hospital, Athens, Greece
    Am J Hematol 77:377-80. 2004
    ..Thus, malignant diseases were excluded and the diagnosis of an extraosseous Gaucher-cell extension was well documented. Our case is reported because it is very interesting and unique in the literature...
  59. ncbi New strategies for MGUS and smoldering multiple myeloma
    Robert A Kyle
    Mayo Clinic Medical School, USA
    Clin Adv Hematol Oncol 2:507, 509. 2004
  60. ncbi [Immunoglobulin heavy chain gene rearrangements in the monoclonal gammopathies]
    Andrea Bosaleh
    Servicio de Patologia, CEMIC, Buenos Aires, Argentina
    Medicina (B Aires) 65:219-25. 2005
    ..The study of immunoglobulin heavy chain gene rearrangements by molecular biology allows a more sensitive detection of clonality...
  61. ncbi Scintigraphy using (99m)Tc-MIBI (sestamibi), a sensitive parameter of activity of multiple myeloma
    J Bacovsky
    3rd Clinic of Internal Medicine, Medical Faculty and University Hospital Olomouc, Olomouc, Czech Republic
    Neoplasma 52:302-6. 2005
    ..Technetium-99m methoxyisobutylisonitrile is a useful indicator of activity of MM and helps in differentiating between multiple myeloma and monoclonal gammopathy of undetermined significance...
  62. ncbi Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma
    Angelo Vacca
    Department of Internal Medicine and Clinical Oncology, Policlinico Piazza Giulio Cesare, University of Medical School Bari, Italy
    J Clin Oncol 23:5334-46. 2005
    ..To study the antiangiogenic effect of thalidomide...
  63. ncbi Treatment of plasma cell dyscrasias with lenalidomide
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens, School of Medicine, Athens, Greece
    Leukemia 22:1343-53. 2008
    ..In this review, we summarize the mechanisms of action, toxicity and clinical activity, and the current role of lenalidomide in patients with multiple myeloma or other related plasma cell disorders...
  64. ncbi Monoclonal gammopathy: natural history studied with a retrospective approach
    Hlif Steingrimsdottir
    Landspitali University Hospital, Department of Clinical Hematology, Reykjavik, Iceland
    Haematologica 92:1131-4. 2007
    ..Excluding light chain or non-secretory disease, 72 % of MM cases had a prodromal MGUS phase within 10 years of diagnosis MM and WM were preceded by MGUS in at least half of the cases, confirming the premalignant nature of this condition...
  65. ncbi [Malignant transformation of monoclonal gammopathy of undetermined significance]
    Olivier Decaux
    Medecine Interne, Département de Médecine de l Adulte, Hopital Sud, Rennes, France
    Presse Med 36:1985-96. 2007
    ..These scores require validation. These scores will probably allow individualization of management and monitoring...
  66. ncbi Review of peripheral neuropathy in plasma cell disorders
    Jeannine Silberman
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Hematol Oncol 26:55-65. 2008
    ....
  67. ncbi Paraproteinemias and the lungs
    Om P Sharma
    Department of Medicine, Keck School of Medicine, Los Angeles, California 90033, USA
    Curr Opin Pulm Med 11:408-11. 2005
  68. ncbi MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells Costimulates pamidronate-activated gammadelta lymphocytes
    Stefania Girlanda
    Laboratory of Tumor Immunology and Department of Oncology, Istituto di Ricerca e Cura a Carattere Scientifico H S Raffaele, Milan, Italy
    Cancer Res 65:7502-8. 2005
    ..Moreover, pamidronate-activated Vgamma9/Vdelta2 lymphocytes can be exploited in the immune therapy of early stages multiple myeloma and possibly of premalignant disease...
  69. ncbi Serum pleiotrophin levels are elevated in multiple myeloma patients and correlate with disease status
    Howard S Yeh
    Institute for Myeloma and Bone Cancer Research, 9201 W Sunset Boulevard, West Hollywood, CA 90069, USA
    Br J Haematol 133:526-9. 2006
    ..001). These results suggest that serum PTN may be a new biomarker for monitoring the disease status and therapeutic response of MM patients...
  70. pmc Clinical implication of centrosome amplification in plasma cell neoplasm
    Wee J Chng
    Division of Hematology Oncology, Mayo Clinic, Johnson Research Bldg, 13400 E Shea Blvd, Scottsdale, AZ, USA
    Blood 107:3669-75. 2006
    ....
  71. ncbi Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma
    Jannie M Rendtlew Danielsen
    Department of Haematology 54P4, Herlev University Hospital, University of Copenhagen, Denmark
    Br J Haematol 138:756-60. 2007
    ..CD47 and TSP1/TSP2 may have a potential role in the pathophysiology of MM, probably in the interaction between MM PCs and the microenvironment...
  72. ncbi Erythema elevatum diutinum with unusual clinical appearance
    Evelyn Soubeiran
    University Dermatology Clinic, Heidelberg, Germany
    J Dtsch Dermatol Ges 6:303-5. 2008
    ..Early treatment with dapsone, corticosteroids and antibiotics is sometimes effective. A patient with multiple myeloma displayed unusual lesions of erythema elevatum diutinum...
  73. ncbi Generalized crystal-storing histiocytosis associated with monoclonal gammopathy: molecular analysis of a disorder with rapid clinical course and review of the literature
    Annette Lebeau
    Pathologisches Institut and the Medizinische Klinik Klinikum Innenstadt der Ludwig Maximilians Universität München, Germany
    Blood 100:1817-27. 2002
    ..Our results suggest that conformational alterations induced by amino acid exchanges represent a crucial pathogenic factor in CSH...
  74. ncbi Aberrant gene promoter methylation in plasma cell dyscrasias
    Paloma Martin
    Laboratory of Molecular Pathology, Department of Pathology, Hospital Universitario Puerta de Hierro, Madrid, Spain
    Exp Mol Pathol 84:256-61. 2008
    ....
  75. ncbi Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma
    C Scavelli
    Department of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy
    Oncogene 27:663-74. 2008
    ..Macrophages may be a target for the MM antivascular treatment...
  76. ncbi Serum free light chains in the diagnosis and monitoring of patients with plasma cell dyscrasias
    Mary M Mayo
    Department of Pathology, Saint Louis University School of Medicine, St Louis, MO 63104, USA
    Contrib Nephrol 153:44-65. 2007
    ..Analytical considerations for the assay are also discussed...
  77. ncbi Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1alpha in patients with multiple myeloma
    Sally K Martin
    Myeloma and Mesenchymal Research Group, Matthew Roberts Foundation Laboratory, Division of Haematology, Institute of Medical and Veterinary Science, University of Adelaide, Australia
    Clin Cancer Res 12:6973-7. 2006
    ..We have now examined whether SDF-1alpha levels also correlate with angiogenesis...
  78. pmc Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma
    Chor Sang Chim
    University Department of Medicine, Queen Mary Hospital, Hong Kong
    J Clin Pathol 60:104-6. 2007
    ..Methylation of DAP kinase and oestrogen receptor genes was comparable in multiple myeloma and MGUS. In conclusion, methylation of p16, SHP1 and E-cadherin genes might be involved in the progression of MGUS to multiple myeloma...
  79. ncbi Should bone marrow examination be routinely performed for the diagnosis of monoclonal gammopathy of undetermined significance?
    Avishay Elis
    Department of Medicine, Meir Medical Center, Kfar Saba, Israel
    Isr Med Assoc J 8:840-2. 2006
    ....
  80. ncbi Focal and segmental glomerulosclerosis and plasma cell proliferative disorders
    David Dingli
    Division of Hematology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Kidney Dis 46:278-82. 2005
    ..FSGS can be caused by a variety of conditions, but it has been reported rarely in association with a plasma cell disorder...
  81. ncbi Demonstration of changes in plasma cell subsets in multiple myeloma
    Michael John Ayliffe
    Department of Immunology, St Helier Hospital Wrythe Lane, Carshalton, Surrey, UK
    Haematologica 92:1135-8. 2007
    ..Progression from cells making intact M-Ig to cells restricted to FLC only production occurred in individual cases during the course of their disease. The presence of FLC only cells was associated with shortened survival...
  82. ncbi Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance
    Shaji Kumar
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 23:5668-74. 2005
    ..Identification of patients with MGUS at high risk of progression will allow development of preventive strategies. We studied the prognostic value of circulating plasma cells (PCs) in patients with MGUS to predict progression...
  83. ncbi From scleredema to AL amyloidosis: disease progression or coincidence? Review of the literature
    Magdalena Dziadzio
    Centre for Rheumatology, Royal Free and University College Medical School, University College, Rowland Hill Street, London, NW 32PF, UK
    Clin Rheumatol 25:3-15. 2006
    ..We discuss the diagnosis of plasma cell dyscrasias and amyloidosis and their relevance in rheumatology practice...
  84. ncbi [Multiple myeloma -- diagnostics]
    R Schroers
    Abteilung Hämatologie und Onkologie, Zentrum Innere Medizin, Universitätsklinikum Göttingen
    Dtsch Med Wochenschr 130:278-82; quiz 287-90. 2005
  85. ncbi Microvessel overexpression of aquaporin 1 parallels bone marrow angiogenesis in patients with active multiple myeloma
    A Vacca
    Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, University School, Bari, Italy
    Br J Haematol 113:415-21. 2001
    ..It may, perhaps, favour angiogenesis in a positive loop and, hence, MM progression, and thus be applied for therapeutic vascular targeting...
  86. ncbi Frequent occurrence of CCND1 deregulation in patients with early stages of plasma cell dyscrasia
    Kazuhisa Miura
    Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Science, Mizuho ku, Nagoya 467 8601, Japan
    Cancer Sci 94:350-4. 2003
    ..This suggests to us that cyclin D1 deregulation due to the presence of t(11;14) is involved in the early development of plasma cell neoplasms, and that this event alone is not enough for the development of symptomatic myeloma...
  87. ncbi Predictive variables for malignant transformation in 452 patients with asymptomatic IgM monoclonal gammopathy
    Enrica Morra
    Department of Hematology and Bone Marrow Transplantation, Niguarda Ca Granda Hospital, Milan, Italy
    Semin Oncol 30:172-7. 2003
    ..0001). In conclusion, patients with asymptomatic IgM-MG showing hematological features predictive of progression should be carefully monitored in view of an early treatment of the disease...
  88. ncbi Whole-body (18)F-FDG PET identifies high-risk myeloma
    Brian G M Durie
    Division of Hematology Oncology, Department of Medicine, Cedars Sinai Comprehensive Cancer Center, Cedars Sinai Medical Center, Los Angeles, California, USA
    J Nucl Med 43:1457-63. 2002
    ..The purpose of this study was to evaluate the clinical utility of whole-body PET with (18)F-FDG in patients with multiple myeloma and related monoclonal diseases...
  89. ncbi Prognostic factors in malignant transformation of monoclonal gammopathy of undetermined significance
    Fausto Adami
    Leuk Lymphoma 43:1713-4. 2002
  90. ncbi [Follow-up of monoclonal gammopathy of undetermined significance in a population of 51 patients older than 70 years ]
    O Decaux
    Département de Médecine de l Adulte, Hopital Sud, 16, boulevard de Bulgarie, 35056 Rennes, France
    Rev Med Interne 23:751-8. 2002
    ..Its incidence is about 3% after 70 years. We have performed a retrospective study of patients aged of more than 70 years who were examined until 1995 for a MGUS...
  91. ncbi Amyloidosis of the tongue as a paraneoplastic marker of plasma cell dyscrasia
    Rutger I F van der Waal
    Department of Dermatology, Vu University Medical Center ACTA, Amsterdam, The Netherlands
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod 94:444-7. 2002
    ..Our objective was to study the results of the medical workup in patients with amyloidosis of the oral cavity...
  92. ncbi Coexistence of beta2 microglobulin and lambda light chain in amyloid fibrils of dialysis-unrelated plasma cell dyscrasia-associated systemic amyloidosis
    N Fujimoto
    Department of Dermatology, National Defense Medical College, Saitama, Japan
    Br J Dermatol 147:549-53. 2002
    ..Systemic amyloidosis occurs as a result of amyloid deposition in various tissues. The amyloid fibrils in systemic amyloidosis have been reported to originate from immunoglobulin light chains...
  93. ncbi Myeloma and macroglobulinemia: what are the criteria for diagnosis?
    Marvin J Stone
    Baylor Charles A Sammons Cancer Center, Dallas 75246, TX, USA
    Clin Lymphoma 3:23-5. 2002
    ..Uniform definitions and consensus on diagnostic standards are becoming increasingly necessary if more effective and less toxic therapeutic approaches for patients with myeloma and macroglobulinemia are to be applied in an optimal manner...
  94. ncbi Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 8:2210-6. 2002
    ..To determine whether bone marrow (BM) angiogenesis progressively increases along the spectrum of plasma cell disorders ranging from monoclonal gammopathy of undetermined significance (MGUS) to advanced myeloma...
  95. ncbi Human herpesvirus 8 genome is not found in whole bone marrow core biopsy specimens of patients with plasma cell dyscrasias
    J J Drabick
    Hematology Oncology Service, Walter Reed Army Medical Center, Washington, DC 20307 5000, USA
    Ann Hematol 81:304-7. 2002
    ..This report adds to the body of evidence that HHV-8 is not associated with plasma cell dyscrasias like multiple myeloma...
  96. ncbi Chromosomal aberrations are shared by malignant plasma cells and a small fraction of circulating CD19+ cells in patients with myeloma and monoclonal gammopathy of undetermined significance
    Niklas Zojer
    First Department of Internal Medicine and Medical Oncology, Wilhelminenspital, University of Vienna, Montleartstrasse 37, 1160 Vienna, Austria
    Br J Haematol 117:852-9. 2002
    ..These results provide evidence that the circulating clonotypic B cells are closely related to the malignant plasma cells in myeloma and MGUS...
  97. ncbi Plasmapheresis in the dysproteinemias
    Mary Jo Drew
    Transfusion Medicine, Henry Ford Hospital Blood Bank, Detroit, Michigan 48202, USA
    Ther Apher 6:45-52. 2002
    ..Results of published studies, case reports, and the author's experience in treating these diseases will serve as the foundation for discussion...
  98. ncbi Detection of CD55- and/or CD59-deficient red cell populations in patients with plasma cell dyscrasias
    John Meletis
    First Department of Internal Medicine, University of Athens School of Medicine, Laiko General Hospital, Greece
    Int J Hematol 75:40-4. 2002
    ..These findings illustrate the existence of the PNH phenotype in the red cells of patients with PCD; further investigation is needed into the mechanisms and significance of this phenotype...
  99. ncbi p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance
    G Guillerm
    , Institut de Recherche sur le Cancer de Lille (IRCL, and the Service des Maladies du Sang, Centre Hospitalier et Universitaire (CHU) Lille, Lille, France
    Blood 98:244-6. 2001
    ..p15(INK4b) and p16(INK4a) gene methylation might contribute to immortalization of plasma cells rather than malignant transformation in the natural history of MM...
  100. ncbi Long-term follow-up of IgM monoclonal gammopathy of undetermined significance
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 102:3759-64. 2003
    ..5 g/dL or less, 26% with 1.5 g/dL, 34% for 2.0 g/dL, and 41% for more than 2.5 g/dL...
  101. ncbi Telomere shortening in patients with plasma cell disorders
    Alejandra Cottliar
    Departamento de Genetica, Instituto de Investigaciones Hematologicas Mariano R Castex, Academia Nacional de Medicina, Buenos Aires, Argentina
    Eur J Haematol 71:334-40. 2003
    ..The aim of this work was to study telomere length (TL) on bone marrow (BM) cells from patients with multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS)...

Research Grants25

  1. NITRIC OXIDE REGULATORY SYSTEM IN THE PENIS
    Arthur Burnett; Fiscal Year: 2002
    ....
  2. Angiogenesis and thalidomide therapy in multiple myeloma
    S Rajkumar; Fiscal Year: 2004
    ..This study offers a unique opportunity to serially study tumor cells and the tumor microenvironment following potential anti-angiogenic therapy. ..
  3. Treatment of Early Stage Multiple Myeloma
    S Rajkumar; Fiscal Year: 2006
    ..BM angiogenesis will be studied using immunostaining (IHC) for CD34 and an in vitro human angiogenesis assay. VEGF expression will be studied using IHC and quantitative RT-PCR. ..
  4. EBV SPECIFIC THERAPY OF LYMPHOMA USING DENDRITIC CELLS
    Madhav Dhodapkar; Fiscal Year: 2002
    ..abstract_text> ..
  5. Neurotrophin Signaling in Multiple Myeloma
    Roger N Pearse; Fiscal Year: 2010
    ....
  6. MECHANISM OF PI-RELATED DYSLIPIDEMIA AND ATHEROSCLEROSIS
    Daniel Rader; Fiscal Year: 2004
    ..These studies will provide novel insights into the mechanisms of PI-associated dyslipidemia and atherosclerosis. ..
  7. Gordon Research Conference: Lipoprotein Metabolism 2004
    Daniel Rader; Fiscal Year: 2004
    ....
  8. CELLULAR BASIS OF ANTIATHEROGENESIS BY APOLIPOPROTEIN E
    Daniel Rader; Fiscal Year: 2001
    ..These studies will provide greater understanding of the role of the local inflammatory response in atherosclerosis and its regulation by apoE. ..
  9. HIV Epitope Specific T Cell Responses and Control of HIV Replication
    Mark Jacobson; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  10. Aberrant T Cell Function and Immunopathogenesis of CMV Immune Recovery Uveitis
    Mark Jacobson; Fiscal Year: 2008
    ..Thus, understanding the disease mechanism of CMV IRU could facilitate development of effective therapy for CMV IRU or diagnostic or treatment strategies to prevent CMV IRU. [unreadable] [unreadable] [unreadable]..
  11. PHENOTYPIC AND PSYCHOSOCIAL STUDY OF THE L1307K MUTATION
    Henry Lynch; Fiscal Year: 2004
    ....
  12. NOVEL SEROTHERAPY STRATEGIES--PLASMA CELL MALIGNANCIES
    STEVEN TREON; Fiscal Year: 2004
    ..Analogous to our work with Muc-1, we will also attempt to identify other PCD selective targets by generating and examining mAbs specific to the plasma cell glycoform of CD138. ..
  13. HDL metabolism: Influence of extracellular lipases
    Daniel Rader; Fiscal Year: 2009
    ....
  14. Mentored Career Development in Patient Oriented Research
    Daniel Rader; Fiscal Year: 2006
    ..abstract_text> ..
  15. A Mayo Cohort Study of Mammographic Breast Density
    Celine Vachon; Fiscal Year: 2007
    ..The findings from these proposed studies have obvious translational implications: high-risk groups can be identified for intervention, more aggressive surveillance and perhaps chemoprevention. [unreadable] [unreadable]..
  16. CMV Immune Response & Long-Term Outcome of CMV Retinitis
    Mark Jacobson; Fiscal Year: 2005
    ....
  17. Adjunct rhIL-12 enhance THI response to viral vaccine?
    Mark Jacobson; Fiscal Year: 2004
    ..g. CMV, HSV and HIV). ..
  18. Phase II Trial of Thalidomide in Primary Amyloidosis
    Angela Dispenzieri; Fiscal Year: 2002
    ..The ultimate goal of the proposed studies is to improve the prognosis of patient with this fatal disease. ..
  19. Dialysis Access Consortium Clinical Trials
    LAURA DEMBER; Fiscal Year: 2006
    ....
  20. 2008 AUA/SBUR Summer Research Conference
    Arthur Burnett; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  21. IMMUNE RESPONSES IN PATIENTS WITH GBS AND CIDP
    AMJAD ILYAS; Fiscal Year: 2002
    ..Early and serial serum specimens from GBS and CIDP patients will be examined to see whether autoantibody titers correlate with disease severity. ..
  22. IMMUNE RESPONSES TO PNEUMOCOCCAL ANTIGENS IN CHILDREN
    Lisa Kobrynski; Fiscal Year: 2003
    ..In addition, the applicant will pursue further training in study design and research methods, including didactic courses at the Rollins School of Public Health and the Graduate Division of Biological and Biomedical Sciences, at Emory. ..
  23. Feline Model of Neuropathy associated with anti-MAG/SGPG antibodies
    AMJAD ILYAS; Fiscal Year: 2007
    ..These studies may lead to the development of a feline model of anti-MAG/SGPG neuropathy that closely resembles the human disorder [unreadable] [unreadable] [unreadable] [unreadable]..
  24. Phase 3 stem cell transplant for light chain amyloidosis
    Morie A Gertz; Fiscal Year: 2011
    ..In addition, the analysis of clonal precursor B cells in the periphery and kinetics of amyloid formation of the monoclonal light chain will allow us to define and determine the mechanisms of disease progression and response to therapy. ..